{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:47:38Z","timestamp":1778698058232,"version":"3.51.4"},"reference-count":130,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T00:00:00Z","timestamp":1438905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxics"],"abstract":"<jats:p>Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a dose-limiting side effect of several antineoplastic drugs which significantly reduces patients\u2019 quality of life. Although different molecular mechanisms have been investigated, CIPN pathobiology has not been clarified yet. It has largely been recognized that Dorsal Root Ganglia are the main targets of chemotherapy and that the longest nerves are the most damaged, together with fast axonal transport. Indeed, this bidirectional cargo-specific transport has a pivotal role in neuronal function and its impairment is involved in several neurodegenerative and neurodevelopmental diseases. Literature data demonstrate that, despite different mechanisms of action, all antineoplastic agents impair the axonal trafficking to some extent and the severity of the neuropathy correlates with the degree of damage on this bidirectional transport. In this paper, we will examine the effect of the main old and new chemotherapeutic drug categories on axonal transport, with the aim of clarifying their potential mechanisms of action, and, if possible, of identifying neuroprotective strategies, based on the knowledge of the alterations induced by each drugs.<\/jats:p>","DOI":"10.3390\/toxics3030322","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T10:25:21Z","timestamp":1438943121000},"page":"322-341","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-4538","authenticated-orcid":false,"given":"Gabriella","family":"Nicolini","sequence":"first","affiliation":[{"name":"Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Monfrini","sequence":"additional","affiliation":[{"name":"Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy"},{"name":"PhD Neuroscience Program, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Scuteri","sequence":"additional","affiliation":[{"name":"Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,8,7]]},"reference":[{"key":"ref_1","unstructured":"Brady, S.T., Siegel, G.J., Albers, R.W., and Price, D.L. (2012). Basic Neurochemistry (Eighth Edition) Principles of Molecular, Cellular, and Medical Neurobiology, Elsevier."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/neu.10319","article-title":"Cargo-carrying motor vehicles on the neuronal highway: Transport pathways and degenerative disease","volume":"58","author":"Gunawardena","year":"2004","journal-title":"J. Neurobiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0074-7696(08)62388-8","article-title":"Microtubules and microtubule motors: Mechanisms of regulation","volume":"164","author":"Thaler","year":"1996","journal-title":"Int. Rev. Cytol."},{"key":"ref_4","first-page":"1177","article-title":"Low potency of taxol at microtubule minus ends: Implications for its antimitotic and therapeutic mechanism","volume":"58","author":"Derry","year":"1998","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuro.2013.05.008","article-title":"Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy","volume":"37","author":"LaPointe","year":"2013","journal-title":"Neurotoxicology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1021\/bi953037i","article-title":"Interaction of vinca alkaloids with tubulin: A comparison of vinblastine, vincristine, and vinorelbine","volume":"35","author":"Lobert","year":"1996","journal-title":"Biochemistry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0006-8993(95)00100-5","article-title":"Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity","volume":"676","author":"Russell","year":"1995","journal-title":"Brain Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","article-title":"The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons","volume":"406","author":"Adelsberger","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1212\/01.WNL.0000049462.03800.B1","article-title":"Thalidomide-induced neuropathy: A ganglionopathy?","volume":"60","author":"Giannini","year":"2003","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuro.2013.09.001","article-title":"Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons","volume":"39","author":"Staff","year":"2013","journal-title":"Neurotoxicology"},{"key":"ref_11","unstructured":"Siegel, G.J., Agranoff, B.W., Albers, R.W., Fisher, S.K., and Uhler, M.D. (1999). Basic Neurochemistry: Molecular, Cellular and Medical Aspects, Lippincott-Raven. [6th ed.]."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2015.01.048","article-title":"Mechanisms of distal axonal degeneration in peripheral neuropathies","volume":"596","author":"Cashman","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"6","author":"Cavaletti","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11916-013-0364-5","article-title":"Emerging trends in understanding chemotherapy-induced peripheral neuropathy","volume":"17","author":"Ferrier","year":"2013","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2011.10.019","article-title":"Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy","volume":"291","author":"Jaggi","year":"2012","journal-title":"Toxicology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): An update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","article-title":"Chemotherapy-induced peripheral neuropathies: From clinical relevance to preclinical evidence","volume":"10","author":"Balayssac","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fphar.2013.00156","article-title":"Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)","volume":"4","author":"Han","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_21","first-page":"389","article-title":"Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration","volume":"21","author":"Cavaletti","year":"2000","journal-title":"Neurotoxicology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clcc.2012.05.002","article-title":"The effect of diabetes on oxaliplatin-induced peripheral neuropathy","volume":"11","author":"Uwah","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","article-title":"Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics","volume":"12","author":"Cavaletti","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1186\/1471-2407-14-993","article-title":"Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes","volume":"14","author":"Park","year":"2014","journal-title":"BMC Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.2014-0044","article-title":"Platinum-induced neurotoxicity and preventive strategies: Past, present, and future","volume":"20","author":"Avan","year":"2015","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2014.12.041","article-title":"Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients","volume":"349","author":"Johnson","year":"2015","journal-title":"Neurol. Sci."},{"key":"ref_28","first-page":"CD005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","volume":"3","author":"Albers","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1158\/1078-0432.CCR-08-0169","article-title":"Microtubule active agents: Beyond the taxane frontier","volume":"14","author":"Morris","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_30","first-page":"204","article-title":"Peripheral neuropathy caused by Paclitaxel and docetaxel: An evaluation and comparison of symptoms","volume":"4","author":"Tofthagen","year":"2013","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_31","first-page":"107","article-title":"Neurotoxicity of Taxol","volume":"15","author":"Rowinsky","year":"1993","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1008245400251","article-title":"Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)","volume":"8","author":"Hilkens","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1432-1033.1982.tb06873.x","article-title":"Dynamic properties of microtubules at steady state in the presence of taxol","volume":"127","author":"Caplow","year":"1982","journal-title":"Eur. J. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/cb200403x","article-title":"Structural evidence for cooperative microtubule stabilization by Taxol and the endogenous dynamics regulator MAP4","volume":"7","author":"Xiao","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12033-009-9193-5","article-title":"On and around microtubules: An overview","volume":"43","author":"Wade","year":"2009","journal-title":"Mol. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11765","DOI":"10.1074\/jbc.M110.162214","article-title":"Hallmarks of molecular action of microtubule stabilizing agents: Effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation","volume":"286","author":"Menon","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31785","DOI":"10.1016\/S0021-9258(18)31764-2","article-title":"Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain","volume":"269","author":"Andreu","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33803","DOI":"10.1074\/jbc.273.50.33803","article-title":"Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics","volume":"273","author":"Valpuesta","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_39","first-page":"1065","article-title":"Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells","volume":"26","author":"Scuteri","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s004410050019","article-title":"Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro","volume":"299","author":"Theiss","year":"2000","journal-title":"Cell Tissue Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-0102(99)00074-7","article-title":"Morphological evidence of the inhibitory effect of taxol on the fast axonal transport","volume":"35","author":"Nakata","year":"1999","journal-title":"Neurosci. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1254\/jphs.09352FP","article-title":"Computational analysis of the effects of antineoplastic agents on axonal transport","volume":"114","author":"Goshima","year":"2010","journal-title":"J. Pharmacol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-009-0586-0","article-title":"Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: Implications for the pathogenesis of paclitaxel-induced polyneuropathy","volume":"119","author":"Shemesh","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0854.2007.00695.x","article-title":"Tau-induced traffic jams reflect organelles accumulation at points of microtubule polar mismatching","volume":"9","author":"Shemesh","year":"2008","journal-title":"Traffic"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"R525","DOI":"10.1016\/j.cub.2004.06.045","article-title":"Bidirectional transport along microtubules","volume":"14","author":"Welte","year":"2004","journal-title":"Curr. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/bfgp\/ell002","article-title":"Towards an understanding of kinesin-1 dependent transport pathways through the study of protein-protein interactions","volume":"5","author":"Gindhart","year":"2006","journal-title":"Brief Funct. Genomic Proteomic"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ceb.2010.04.008","article-title":"Linking molecular motors to membrane cargo","volume":"22","author":"Akhmanova","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12776","DOI":"10.1523\/JNEUROSCI.3463-09.2009","article-title":"Axonal transport defects in neurodegenerative diseases","volume":"29","author":"Morfini","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_49","first-page":"1851","article-title":"Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway","volume":"56","author":"Blagosklonny","year":"1996","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1523\/JNEUROSCI.21-13-04657.2001","article-title":"Taxol induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 phosphorylation","volume":"21","author":"Hetman","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0197-0186(02)00132-8","article-title":"Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells","volume":"42","author":"Nicolini","year":"2003","journal-title":"Neurochem. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nn1717","article-title":"JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport","volume":"9","author":"Morfini","year":"2006","journal-title":"Nat. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"32612","DOI":"10.1074\/jbc.M113.515510","article-title":"Motor domain phosphorylation modulates kinesin-1 transport","volume":"288","author":"DeBerg","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1091\/mbc.e09-01-0044","article-title":"Posttranslational modifications of tubulin and the polarized transport of kinesin-1 in neurons","volume":"21","author":"Hammond","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbadis.2004.07.002","article-title":"Inability of tau to properly regulate neuronal microtubule dynamics: A loss-of-function mechanism by which tau might mediate neuronal cell death","volume":"1739","author":"Feinstein","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bpj.2009.04.047","article-title":"Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: A synchrotron x-ray scattering study","volume":"97","author":"Choi","year":"2009","journal-title":"Biophys. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0002-9440(10)65533-2","article-title":"Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein","volume":"155","author":"Spittaels","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1083\/jcb.200108057","article-title":"Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress","volume":"156","author":"Stamer","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.neurobiolaging.2003.04.007","article-title":"Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses","volume":"24","author":"Mandelkow","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/375424a0","article-title":"Structure of tubulin at 6.5 A and location of the taxol-binding site","volume":"375","author":"Nogales","year":"1995","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/emboj\/cdg001","article-title":"Repeat motifs of tau bind to the insides of microtubules in the absence of taxol","volume":"22","author":"Kar","year":"2003","journal-title":"EMBO J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1242\/jcs.01531","article-title":"Tau interaction with microtubules in vivo","volume":"117 Pt 25","author":"Samsonov","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1523\/JNEUROSCI.07-11-03695.1987","article-title":"Taxol interferes with the interaction of microtubule-associated proteins with microtubules in cultured neurons","volume":"7","author":"Black","year":"1987","journal-title":"J. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/1097-0142(19910501)67:9<2241::AID-CNCR2820670905>3.0.CO;2-A","article-title":"Evolution of neuropathy and myopathy during intensive vincristine\/corticosteroid chemotherapy for non-Hodgkin\u2019s lymphoma","volume":"67","author":"DeAngelis","year":"1991","journal-title":"Cancer"},{"key":"ref_65","first-page":"963","article-title":"Augmentation of vincristine neurotoxicity by irradiation of peripheral nerves","volume":"64","author":"Cassady","year":"1980","journal-title":"Cancer Treat. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00255486","article-title":"Can severe vincristine neurotoxicity be prevented?","volume":"8","author":"Desai","year":"1982","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-510X(70)90013-4","article-title":"The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies","volume":"10","author":"Bradley","year":"1970","journal-title":"J. Neurol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","article-title":"Chemotherapy-induced peripheral neuropathy: Prevention and treatment","volume":"90","author":"Pachman","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuroscience.2011.10.010","article-title":"Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat","volume":"199","author":"Xiao","year":"2011","journal-title":"Neuroscience"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/(SICI)1096-9861(19980615)395:4<481::AID-CNE5>3.0.CO;2-Y","article-title":"Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat","volume":"395","author":"Tanner","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U","article-title":"Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat","volume":"424","author":"Topp","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1523\/JNEUROSCI.18-16-06480.1998","article-title":"Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat","volume":"18","author":"Tanner","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp.61.4.409","article-title":"Vinorelbine neurotoxicity: Clinical and neurophysiological findings in 23 patients","volume":"61","author":"Pace","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/17425255.2014.885016","article-title":"Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies","volume":"10","author":"Said","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminoncol.2005.09.013","article-title":"Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)","volume":"32","author":"Lee","year":"2005","journal-title":"Semin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-008-0724-8","article-title":"Preclinical discovery of ixabepilone, a highly active antineoplastic agent","volume":"63","author":"Lee","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1535-7163.MCT-08-0999","article-title":"Discovery of ixabepilone","volume":"8","author":"Hunt","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.clinthera.2008.09.015","article-title":"Ixabepilone: A novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer","volume":"30","author":"Steinberg","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/092986709787846488","article-title":"Tubulin: A target for antineoplastic drug into the cancer cells but also in the peripheral nervous system","volume":"16","author":"Canta","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jpainsymman.2011.02.022","article-title":"Epothilone-induced peripheral neuropathy: A review of current knowledge","volume":"42","author":"Argyriou","year":"2011","journal-title":"J. Pain Symptom Manag."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1002\/anie.200602785","article-title":"Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development","volume":"45","author":"Klar","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1158\/0008-5472.CAN-08-0237","article-title":"Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone","volume":"68","author":"Hoffmann","year":"2008","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1215\/15228517-2008-072","article-title":"Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases","volume":"11","author":"Hoffmann","year":"2009","journal-title":"Neuro Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clbc.2011.03.024","article-title":"A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases","volume":"11","author":"Freedman","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/annonc\/mdq729","article-title":"Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group","volume":"22","author":"Stupp","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1021\/bi010343p","article-title":"Microtubule structure at improved resolution","volume":"40","author":"Kasparian","year":"2001","journal-title":"Biochemistry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: A pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res. Treat"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/cncr.26569","article-title":"Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study","volume":"118","author":"Hensley","year":"2012","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1016\/j.bmcl.2004.08.068","article-title":"Structurally simplified macrolactone analogues of halichondrin B","volume":"14","author":"Seletsky","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_95","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ctrv.2011.03.006","article-title":"Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer","volume":"38","author":"Cortes","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0162-0134(99)00135-X","article-title":"Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches","volume":"77","author":"Screnci","year":"1999","journal-title":"J. Inorg. Biochem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2174\/092986708786848569","article-title":"Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies","volume":"15","author":"Park","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1200\/JCO.1989.7.10.1457","article-title":"Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer","volume":"7","author":"Hansen","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI1130","article-title":"Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle","volume":"101","author":"Gill","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.2174\/138161212802002634","article-title":"Review of dose-intense platinum and\/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer","volume":"18","author":"Boere","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_104","first-page":"3797","article-title":"Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients","volume":"18","author":"Cavaletti","year":"1998","journal-title":"Anticancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","article-title":"Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures","volume":"29","author":"Gamelin","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1152\/jn.2001.85.5.2293","article-title":"A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels","volume":"85","author":"Grolleau","year":"2001","journal-title":"J. Neurophysiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2011.08.016","article-title":"Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy","volume":"232","author":"Zheng","year":"2011","journal-title":"Exp. Neurol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e45776","DOI":"10.1371\/journal.pone.0045776","article-title":"Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging","volume":"7","author":"Schellingerhout","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_110","first-page":"77","article-title":"Thalidomide: From tragedy to promise","volume":"133","author":"Stolz","year":"2003","journal-title":"Swiss Med. Wkly."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0753-3322(01)00146-9","article-title":"Thalidomide in cancer","volume":"56","author":"Singhal","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9343(99)00408-8","article-title":"Thalidomide: Current and potential clinical applications","volume":"108","author":"Calabrese","year":"2000","journal-title":"Am. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.4081\/hr.2015.5704","article-title":"Central neurotoxicity of immunomodulatory drugs in multiple myeloma","volume":"7","author":"Patel","year":"2015","journal-title":"Hematol. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1212\/01.WNL.0000130499.91775.2C","article-title":"Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus","volume":"62","author":"Briani","year":"2004","journal-title":"Neurology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","article-title":"Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy","volume":"2","author":"Areti","year":"2014","journal-title":"Redox Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuro.2014.02.001","article-title":"Neurotoxicity induced by antineoplastic proteasome inhibitors","volume":"43","author":"Bruna","year":"2014","journal-title":"Neurotoxicology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1529-8027.2010.00287.x","article-title":"Bortezomib-induced inflammatory neuropathy","volume":"15","author":"Saifee","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","article-title":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","volume":"119","author":"Ravaglia","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e72995","DOI":"10.1371\/journal.pone.0072995","article-title":"Bortezomib-induced painful peripheral neuropathy: An electrophysiological, behavioral, morphological and mechanistic study in the mouse","volume":"8","author":"Carozzi","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12624","article-title":"Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma","volume":"164","author":"Azoulay","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clinph.2013.07.014","article-title":"Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy","volume":"125","author":"Nasu","year":"2014","journal-title":"Clin. Neurophysiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur. J. Pain"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/cc.27476","article-title":"Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy","volume":"13","author":"Meregalli","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1345\/aph.1R561","article-title":"Carfilzomib: A second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"47","author":"Thompson","year":"2013","journal-title":"Ann. Pharmacother."}],"container-title":["Toxics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6304\/3\/3\/322\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:50:25Z","timestamp":1760215825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6304\/3\/3\/322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,7]]},"references-count":130,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["toxics3030322"],"URL":"https:\/\/doi.org\/10.3390\/toxics3030322","relation":{},"ISSN":["2305-6304"],"issn-type":[{"value":"2305-6304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,7]]}}}